FDA汇总分析:仅骨转移乳腺癌对临床试验结局与影像评估的影响
该汇总分析纳入2005年以来提交的13项前瞻性试验中10,521例转移性乳腺癌患者,比较仅骨转移(BO)、骨合并其他转移(BWO)及无骨转移(NBM)亚组的结局与影像学评估差异。BO占12.5%(范围4%-26%),研究者评估的PFS和OS均优于其他亚组,且BO亚组早期不一致率更高、晚期不一致率更低。
要点
- BO占转移性乳腺癌12.5%,比例随亚型而异(范围4%-26%)。
- 研究者评估BO亚组PFS和OS均优于BWO和NBM亚组。
- BO亚组早期影像不一致率高于其他亚组,晚期不一致率更低。
核心结论
- BO转移性乳腺癌可能具有独特的自然病史。
- BO亚组中研究者评估进展事件的方式与其他两组存在差异。
研究设计与样本
- 汇总分析2005年以来提交的13项前瞻性试验中10,521例转移性乳腺癌患者数据。
- 按BO、BWO、NBM三个亚组评估结局。
- 早期和晚期不一致率分别基于3,733例和2,813例接受盲法独立中心审查的患者计算。
主要发现
- 各试验中骨转移患者占49%(范围42%-73%),BO占12.5%(范围4%-26%),比例取决于亚型。
- 研究者评估BO vs BWO的PFS HR为0.64(95% CI 0.591-0.696),BO vs NBM的PFS HR为0.70(95% CI 0.65-0.76)。
- 研究者评估BO vs BWO的OS HR为0.56(95% CI 0.50-0.61),BO vs NBM的OS HR为0.68(95% CI 0.61-0.76)。
- BO亚组早期不一致率高于BWO和NBM亚组,晚期不一致率低于BWO和NBM亚组。
临床怎么用
- 在临床试验和临床实践中解读BO亚组的影像学进展时需注意研究者评估与盲法独立中心审查的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The outcome and proportion of patients with bone-only (BO) metastatic breast cancer (MBC) has not been well described. We sought to describe the differential outcomes of patients with BO MBC in clinical trials and explore whether there was a discrepancy in radiographic reads between investigator and blinded independent central review. Methods We pooled and analyzed data on 10,521 patients from 13 prospective trials submitted for MBC treatment in initial or supplemental New Drug or Biologics License Applications from 2005. Three subsets were evaluated: BO, bone with other metastases (BWO), and no bone metastases (NBM). Early discordance rate and late discordance rate were calculated from 3,733 and 2,813 patients subject to a blinded independent central review, respectively. Results Bone metastases were identified in 49% (range: 42% to 73%) of patients across trials. BO disease was present in 12.5% (range: 4% to 26%), dependent on subtype. Investigator-assessed progression-free survival (PFS) and overall survival (OS) for the pooled trials demonstrated improved outcomes for the BO subgroup compared with other subgroups (BO v BWO PFS hazard ratio [HR], 0.64; 95% CI, 0.591 to 0.696; BO v NBM PFS HR, 0.70; 95% CI, 0.65 to 0.76; BO v BWO OS HR, 0.56; 95% CI, 0.50 to 0.61; BO v NBM OS HR, 0.68; 95% CI, 0.61 to 0.76). The BO subgroup has a higher early discordance rate and lower late discordance rate than the BWO and NBM subgroups. Conclusion To our knowledge, this review is the largest analysis to date of the BO subgroup of MBC and suggests this subgroup may have a distinct natural history. There also seems to be a difference in how the local investigators assessed progression events in the BO subgroup when compared with the other two groups.
引用
- Wedam SB, Beaver JA, Amiri-Kordestani L, et al. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018. PMID: 29522361. doi:10.1200/JCO.2017.74.6917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。